Our Approach to Our Research
- To generate biologically active recombinant human peptide hormones in the Growth Hormone (GH) field with an extended serum half-life using a cultured plant cell system.
- To use Mouse models of type 1, type 2 diabetes and aging
- Genomics approach
- Microarray approach
- Proteomic approach
- To analyze human serum, before and after surgical or medical intervention.
- Individual patients (several types of endocrine disorders)
- Proteomics approach (serum)
- Genomics approach (WBCs)
DiAthegen's Research Effort is carried out via a Sponsored Research Agreement (SRA) with Ohio University's Edison Biotechnology Institute. The research in the areas of Growth, Obesity, and Diabetes is lead by Dr. John Kopchick. O-linked glycosylation (g) technology was orginally discovered by Dr. Kieliszewski and her colleagues at Ohio University. The work on g-rhGH and g-rhGH antagonists (A) is carried out in both Dr. Kopchick's and Dr. Kieliszewski's laboratories.
DiAthegen's strengths are in the areas of Molecular Biology, Trangenic and Knock Out Mouse Models, Physiology, and Pharmacology. Also, Dr. Kopchick's group discovered GHAs in the late 1980s. This discovery has lead to a drug, Somavert, that is currently marketed by Pfizer for acromegaly. Our strengths also include collaborations with many pharmaceutical companies and many clinical research investigators.
Thus, DiAthegen and its team of scientists have a proven track record, a great team of researchers, and
a portfolio of granted and pending patents.